| Literature DB >> 34084194 |
Amir Hossein Siadat1, Fariba Iraji1, Azadeh Zolfaghari1, Sheila Shariat1, Safoura Bokaie Jazi2.
Abstract
Cutaneous leishmaniasis (CL) is endemic in many parts of the world with a high economic and health impact. Despite many treatments that have been suggested for this zoonotic infection, there is still no definite therapy for CL. Meglumine antimony compounds are considered as a standard treatment for leishmaniasis, however, these medications have a relatively high side effect profile and not always effective. Physical modalities including cryotherapy, laser, and heat therapy have also been used for this purpose. As a source of heat therapy, different methods have been used including radiofrequency, ultrasound, infrared, exothermic crystallization thermotherapy, and microwave. We reviewed all of the articles in PubMed regarding the use of heat therapy for the treatment of CL up to January 2020. According to our literature review, heat therapy using different sources showed promising results for the treatment of CL that were comparable to meglumine antimony. In addition, heat therapy has very low side effect profiles that are localized to the treatment area suggesting this method as a safe procedure for CL therapy. This study is a brief review of the literature about the effect of heat therapy on the treatment of CL. Performing randomized clinical trials to compare different methods of heat therapy and to compare it with meglumine antimony compounds is recommended. Copyright:Entities:
Keywords: Cutaneous; leishmaniasis; thermotherapy
Year: 2021 PMID: 34084194 PMCID: PMC8106408 DOI: 10.4103/jrms.JRMS_934_19
Source DB: PubMed Journal: J Res Med Sci ISSN: 1735-1995 Impact factor: 1.852
Summary of the studies used radiofrequency as a source of heat therapy for treatment of cutaneous leishmaniasis
| Reference | Year | Country | Type of leishmaniasis | Groups and number of patients | Protocol of RF | Results (cure rate) |
|---|---|---|---|---|---|---|
| [ | 1990 | Guatemala | 22 patients in systemic glucantime group 22 patients in RF group 22 patients in placebo group | 50°C for 30 s 3 treatment 7-day intervals Devise used: RF generator | Systemic glucantime: 16 (73%) RF: 16 (73%) Placebo: 6 (27%) | |
| [ | 1997 | Mexico | 201 patients in RF | Single application 50°C for 30 s (LCF-RF) | RF: 90% cure rate | |
| [ | 2005 | Afghanistan | 148 patients in IL-SSG group | Application at 50°C for 30 s RF generator (ThermoMed 1.8; Thermosurgery Technologies) | 1 IL-SSG: 70/93 (75.3%) ≥1 IM-SSG: 26/58 (44.8%) RF: 75/108 (69.4%) | |
| [ | 2007 | Iran | Anthroponotic | 57 patients with 83 lesions in RF group 60 patients with 94 lesions in IL glucantime | 50° for 30 s once weekly for 4 weeks RF heat generator (4 MHz, maximum Output 90 W; Ellman International Inc., NY, USA) | RF group: 80.7% IL glucantime group: 55.3% |
| [ | 2013 | India | 50 patients in RF 50 patients in IL-SSG (7 session) | 30-60 s RF ThermoMed 1.8 LCF-RF generator (Thermosurgery Technologies, Arizona, USA) | RF group: 98% IL-SSG: 94% (side effect: none was reported) | |
| [ | 2013 | Colombia | 149 patients in RF group 145 patients in miltefosine group | RF: 50°C for 30 s (ThermoMed®, Thermosurgery Inc., Phoenix, USA) | RF group: 59% Miltefosine group: 59% (side effect: none) | |
| [ | 2009 | Colombia | 47 patients in thermotherapy group 59 patients in MA group | One time 50°C for 30 s ThermoMed 1.8 LCF-RF generator (Thermosurgery Technologies, Arizona, USA) | RF protocol cure rate: 100% | |
| [ | 2010 | Iraq Afghanistan | 27 patients in systemic SSG group 27 patients in RF group | One time: 50°C for 3 s ThermoMed (TM) | Per lesion efficacy SSG: 59% TM: 73% (side effect: blistering, oozing, erythema) | |
| [ | 2012 | Afghanistan | 390 patients in 2 groups 195 patients in RF group 195 patients in IL glucantime group | One-time thermotherapy 50°C for 30 s (ThermoMed 1.8; Thermosurgery Technologies, Phoenix, Arizona) | RF: 82.5% cure rate IL glucantime: 74% cure rate | |
| [ | 2018 | Brazil | Not identified | 15 patients in RF group | 50°C for 30 s (ThermoMed) Model 1.8 (1 session) ThermoMed Model 1.8 (Thermosurgery Technologies, Inc., Phoenix, AZ, USA) | RF Group: 85.7% (side effect: pain, itch, burning sensation, blister) |
| [ | 1992 | Sudan | 1 patient with 10 red nodules and plaques | 50°C surface temperature for 30 s A handheld RF heat generator (RDM Engineering Inc., Phoenix, Arizona) | Six weeks after initial treatment: all lesions were almost completely granulated At 6 months after treatment, the lesions showed complete healing | |
| [ | 2012 | Colombia | 149 patients in RF group 143 patients in systemic MA group | One-time 50°C thermotherapy for 30 s (ThermoMed®, Thermosurgery Inc., Phoenix, USA) | RF: 64% full cure MA: 85% full cure (side effect: Local pain, especially 4 days after initiation of therapy) | |
| [ | 2017 | Sri Lanka | 93 patients in RF group 115 patients in IL-SSG group | ThermoMed Model 1·8 | RF: 65.9% IL-SSG: 59.4% (no side effect) |
L. braziliensis=Leishmania braziliensis; L. mexicana=Leishmania mexicana; L. tropica=Leishmania tropica; L. panamensis=Leishmania panamensis; L. major=Leishmania major; L. amazonensis=Leishmania amazonensis; L. infantum=Leishmania infantum; L. donovani=Leishmania donovani; RF=Radiofrequency; IL=Intralesional; SSG=Sodium stibogluconate; MA=Meglumine antimoniate; LCF: Localized current field; IM=Intramuscularly